MARS Bioimaging received FDA 510(k) clearance for its portable photon-counting CT scanner for upper extremity imaging.
Designed for use in community and point-of-care settings, the MARS Bioimaging Extremity Scanner System delivers high-resolution 3D X-ray images that visualize soft tissue, bone, blood vessels and metallic implants with clear material differentiation.
Dr. Ojas Mahapatra, Group CEO, MARS Bioimaging, said, “FDA clearance represents a pivotal milestone for MARS Bioimaging. In addition to enabling commercial rollout in the United States, it provides important validation that supports regulatory pathways and market adoption globally.”
MARS Bioimaging received FDA 510(k) clearance for its portable photon-counting CT scanner for upper extremity imaging.
Designed for use in community and point-of-care settings, the MARS Bioimaging Extremity Scanner System delivers high-resolution 3D X-ray images that visualize soft tissue, bone, blood vessels and metallic implants with clear...
MARS Bioimaging received FDA 510(k) clearance for its portable photon-counting CT scanner for upper extremity imaging.
Designed for use in community and point-of-care settings, the MARS Bioimaging Extremity Scanner System delivers high-resolution 3D X-ray images that visualize soft tissue, bone, blood vessels and metallic implants with clear material differentiation.
Dr. Ojas Mahapatra, Group CEO, MARS Bioimaging, said, “FDA clearance represents a pivotal milestone for MARS Bioimaging. In addition to enabling commercial rollout in the United States, it provides important validation that supports regulatory pathways and market adoption globally.”
Copy to clipboard 
